Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2016

View Archived Issues

XT-150 as a potential solution for opioid abuse crisis

Array BioPharma and Asahi Kasei Pharma establish strategic collaboration in pain and inflammation

Morphotek and AREVA Med to investigate ontuxizumab conjugated with lead-212

Astellas announces a new collaborative research agreement with AIST

Astellas and LEO Pharma announce the closing of transaction to transfer global dermatology business

Janssen discontinues phase III development of fulranumab for osteoarthritis pain

Guizhou Bailing Group Pharmaceutical discloses alpha-glucosidase inhibitors

Active Biotech patents S100A9 inhibitors

Bristol-Myers Squibb presents peroxidase inhibitors

Eli Lilly develops PDE4B inhibitors

Calreticulin antibody useful in the assessment of bone marrow biopsies

Array BioPharma discontinues MILO study of binimetinib

Amicus' migalastat gets positive opinion from EMA for Fabry disease

EMA's CHMP backs approval of Trevicta for schizophrenia

Samsung Bioepis' infliximab biosimilar receives positive opinion in E.U.

Positive interim results obtained in phase III trial of masitinib in ALS

CHMP recommends approval of Strimvelis for ADA-SCID

BMS's acquisition of Padlock Therapeutics completed

Xilonix will undergo accelerated assessment in E.U.

APE1 and MTH1 may be useful biomarkers for the diagnosis of breast cancer

IXICO announces two milestones concerning its Parkinson's disease franchise

Meiji Seika Pharma receives marketing rights for Ultibro and Seebri from Novartis Pharma in Japan

EMA committee recommends approval of pandemic influenza vaccine

Bionomics begins phase I trial for BNC-101 in metastatic colorectal cancer

CHMP supports E.U. approval of daratumumab

Acetylon Pharmaceuticals reports HDAC6 inhibitors

New bromodomain inhibitor shows promising preclinical results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...